Individuals labelled as having hypertension tend to report poor self-rated health (SRH), but it is unclear whether this association is independent of actual hypertension, socioeconomic status and adiposity, and extends across racial and ethnic groups. In a cross-sectional study we compared hypertensive and normotensive individuals (N ¼ 19 057) who varied in whether they had ever been labelled hypertensive. Blood pressure was measured in participants' homes and mobile examination centres in the United States as part of the Third National Health and Nutrition Examination Survey, 1988Survey, -1994. The main outcome measure was global SRH. Hypertensive labelling was associated with poorer SRH and was independent of established SRH predictors, antihypertensive medication use, body mass index, and hypertension status (adjusted odds ratio (OR) ¼ 1.79, 95% confidence interval (CI), 1.61-1.99). Hypertension was also associated with poorer SRH (OR ¼ 1.26; 95% CI 1.09-1.46) but this association was eliminated by adjustment for hypertensive labelling (OR 1.06; 95% CI 0.92-1.22). These effects were consistent across non-Hispanic white, non-Hispanic black, and Hispanic subgroups. Individuals labelled hypertensive are more likely to have lower SRH and this labelling effect predominates over that of actual hypertension. Public health efforts to increase the number of individuals screened for high blood pressure may successfully detect the presence of hypertension but may also reduce health-related quality of life as measured by global SRH.
Introduction
Screening and detection of hypertension is an enormous and important task. Hypertension is an asymptomatic condition that affects 30% or more of adults and strongly predicts risk of stroke, coronary artery disease, congestive heart failure and renal failure. 1, 2 Many millions of hypertensive individuals remain unaware of their condition 3 and, in response, public health guidelines recommend increasing the proportion of adults screened for high blood pressure. 4 However, screening and detection leads to the labelling of individuals as hypertensive and such labelling may adversely affect some health indices. For example, some studies show that labelling increases work absenteeism [5] [6] [7] while others show that labelled hypertensives have lower selfrated health (SRH) than normotensives. [8] [9] [10] [11] [12] [13] [14] [15] This apparent SRH effect of labelling has been reported in comparisons of labelled and unlabelled (unaware hypertensive) persons 11 and may occur in individuals mislabelled (i.e., normotensive persons misdiagnosed as hypertensive). 9 Therefore, even though screening and detection of hypertension is necessary to prevent the complications of hypertension, it may also adversely impact global SRH through labelling effects.
The potential sensitivity of global self-health ratings to hypertension labelling is particularly important. First, SRH has a prominent role in clinical investigation because subjective ratings of health and well-being are considered to be primary end points. 16 Further, global SRH is an integrative measure of health status that has established criterion validity impacting major objective health outcomes. For example, global SRH covaries with functional ability, 17, 18 prospectively predicts physician use 19 and mortality across socioeconomic strata 20 even after adjustment for objective disease. [21] [22] [23] The predictive utility of SRH is in part why it is routinely collected in public health surveys. 24 For example, the global SRH assessment -'How would you rate your health, poor, fair, good, very good or excellent?' -is a benchmark for quality of life in the national strategy for health promotion in the US. 4 In fact, the first goal of this effort 'y is to help individuals of all ages increase life expectancy and improve their quality of life [emphasis in original]' (p 20). 4 Thus, quality of life on a population level is operationally defined in part by global self-health appraisals like those shown to be sensitive to hypertension labelling. 8, 9, [11] [12] [13] 25 If blood pressure screening and concomitant hypertensive labelling reduce SRH, then success in some elements of public health promotion (blood pressure screening and hypertension control) may erode progress in others (quality of life), particularly for those who are mislabelled.
Our understanding of the scope and character of hypertensive labelling effects on SRH is limited for several reasons. Prior studies have utilized clinic 10, 25 or otherwise restricted samples, 9, 12 enrolled unusually hypertensive subgroups, 25, 26 lacked normotensive controls, 27 and/or did not covary potential confounding factors such as antihypertensive treatments, 8 socioeconomic status, 10, 12, 27 body mass index (BMI), 26, 28 and concurrent chronic disease. 10, 25 Population-based studies with adequate controls were either small 11, 13 or lacked independent blood pressure measurements, 8, 15 and none have enrolled sufficient numbers of racial/ethnic subgroups to evaluate the consistency of labelling effects across non-Hispanic white, non-Hispanic black, and Hispanic subpopulations. Finally, in order to distinguish labelling effects from the effects of hypertension status it is necessary to examine large samples including hypertensive and normotensive individuals, both labelled and unlabelled (or mislabelled, as the case may be).
The present study evaluated hypertension labelling effects on global SRH in the Third National Health and Nutrition Examination Survey (NHANES III), 29, 30 a large, ethnically diverse, probability sample of US residents. These data contain detailed demographic assessments, medical histories, as well as objective measurements of physical characteristics including blood pressure and BMI. Its large scope (over 19 000 adult participants) provides a unique opportunity to address labelling effects independent of actual blood pressure levels, antihypertensive treatment and potential confounding factors. This disaggregation of measured blood pressure from hypertension labelling permits evaluation of the relative impact of risk labelling and actual health risk status. We tested the following hypotheses: (1) Is hypertensive labelling associated with poor SRH?, (2) Is hypertension status (actual blood pressure) associated with poor SRH?, (3) Is the effect of hypertensive labelling similar among normotensives and hypertensives?, and (4) Are these relations consistent across racial/ethnic groups?
Materials and methods
NHANES III utilizes a complex, stratified multistage sampling design that represents the civilian noninstitutionalized population of the US. 30 Blacks, older adults, and Mexican-Americans were oversampled. Participants were interviewed in their home in English or Spanish by NHANES staff, and following the interview physical measurements were obtained by a trained health professional. Additional blood pressure measurements were obtained for most (80%) participants by a boardeligible physician during a second physical exam at a mobile examination centre. The second assessments took place within 4 weeks of the home interview.
Blood pressure was measured with a mercury sphygmomanometer using protocols established by the American Heart Association. Household and mobile examination centre examiners initially received a day and a half of blood pressure measurement training, were recertified quarterly and retrained annually. 29 Of the 20 050 participants in the adult survey (17-90 þ years old), we restricted our analyses to those 18 years and over (N ¼ 19 618) who had at least one valid blood pressure measurement and responded to the question about previously diagnosed hypertension (N ¼ 19 057; 97% of those X18 years old). All participants provided informed consent for both the home and mobile examination centre evaluations. The data used for this study are publicly available from the US National Center for Health Statistics. . Approximately 10% of household income responses were missing. Rather than reducing our sample via casewise deletion, missing income values were imputed using age, education, gender, ethnicity, and smoking status. The direction and significance of analyses were insensitive to this imputation, so we retained the imputed income variable for all analyses.
Measures
Health characteristics. BMI was calculated as weight in kg/height in m 2 . Measurements were obtained by physical examination. We created five BMI categories as follows: underweight (BMI o18.5), normal (BMI 18.5-24.9); overweight (BMI 25-29.9) obese (BMI 30-39.9) and extreme obesity (BMIX40). 31 Four dummy codes were used to represent these five categories. The number of physician visits in the last 12 months (during the past 12 months, about how many times did you see or talk to a medical doctor or assistant?) were recoded into four categories (none, 1, 2, 3, or more). Physician visits are higher among labelled normotensives and may explain differences in health perceptions. 32 Chronic disease was assessed by the self-reported presence or absence of cancer, stroke, heart attack, and diabetes. Smoking status was coded as never, former, or current. A very small number (o0.5%) of missing values for health characteristics were imputed using age, gender, ethnicity, education, household income, and smoking status. Analyses were insensitive to these imputations so we report statistics using the 19 057 adult participants described above.
Hypertensive status and hypertensive label status. We created a binary hypertension status variable (hypertension if systolic blood pressure (SBP)X140 or diastolic blood pressure (DBP)X90; otherwise normotensive) based upon the average of blood pressure readings obtained during the home and mobile examination centre exams. In over 80% of participants this average was derived from six blood pressure measurements across the two sessions, and over 99% of the sample had at least three readings from one session. A binary hypertension label variable was created based upon each participant's answer to the question 'Have you ever been told by a doctor or other health professional that you had hypertension, also called high blood pressure?' These two variables were used to create a 2 Â 2 matrix from which specific pairwise comparisons were conducted (see Table 1 
Statistical analyses
The primary dependent variable was SRH, assessed with the question 'Would you say your health in general is excellent, very good, good, fair, or poor?' Since SRH is an ordered categorical variable, we used an ordinal regression model, the cumulative odds model 33, 34 to evaluate differences in SRH as a 
Results
Across all participants, those labelled as hypertensive were 1.79 times more likely to have poorer SRH than unlabelled persons (95% CI 1.61-1.99, Po0.001). This association was not affected by adjustment for blood pressure (OR ¼ 1.77; 95% CI 1.59-1.97, Po0.001) and was appreciably stronger than the association with low household income (OR ¼ 1.26; 95% CI 1.20-1.33) and low education (OR ¼ 1.43; 95% CI 1.37-1.50). Hypertension status based upon measured blood pressure was also associated with poorer SRH (OR ¼ 1.26; 95% CI 1.09-1.46, Po0.01), but this association was eliminated by adjusting for hypertensive labelling (OR ¼ 1.06; 95% CI 0.92-1.22, P ¼ 0.40). Among normotensives, those labelled as hypertensive were 1.79 (95% CI 1.57-2.04, Po0.001) times more likely to have poorer SRH, an association that was unaffected by controlling for blood pressure. Individuals with normal measured blood pressure but who had been labelled as hypertensive include persons with controlled hypertension (i.e., on treatment) and persons mislabelled (i.e., 'false positives'). To examine the effects of mislabelling among normotensives, we identified the subset of labelled normotensives who were not receiving antihypertensive medication (N ¼ 391) and compared them to unlabelled normotensives. Among unmedicated normotensives the presence of a label was strongly associated with poorer SRH (OR ¼ 2.01; 95% CI 1.37-2.94, P ¼ 0.001).
Among those with high blood pressure, labelled individuals were also more likely to report poorer SRH than unlabelled individuals (OR 1.70; 95% CI 1.42-2.03, Po0.001). This association was unaffected by adjustment for blood pressure (OR 1.68; 95% CI 1.38-2.04, Po0.001) and persisted when the analysis was restricted to hypertensive individuals not receiving hypertensive medication (OR 1.88; 95% CI 1.50-2.34, Po0.001). Finally, we repeated these analyses within the three racial/ethnic groups. The pattern of poorer SRH for labelled individuals was consistent for non-Hispanic whites, non-Hispanic blacks, and Mexican-Americans, while SRH was insensitive to actual hypertension status when labelling was controlled (see Figure 1 ). This pattern was also observed within normotensive and hypertensive participants (see Figure 2 ). Similar patterns were observed for men and women separately (data not shown).
Discussion
We found a consistent and substantial association between hypertension labelling and lower SRH in a large, ethnically diverse sample representative of the US population. Individuals with hypertensive labels had consistently higher odds of poorer selfhealth ratings compared to individuals not so labelled. This relation persisted when comparing 1.07 1.00 1.02 Figure 1 Odds of lower self-rated health by race/ethnicity, hypertension label status and hypertension status. All values are adjusted for age, gender, education, annual household income, body mass index, smoking, physician visits in the last 12 months and the presence of cancer, stroke, heart attack, and diabetes. BP, blood pressure; CI, confidence interval.
normotensives who differed only in their label status, that is, likely false positives (those who were labelled but normotensive without medication) versus true normotensives. Labelling effects were insensitive to actual hypertensive status and, furthermore, hypertensive status based on measured blood pressure did not predict SRH independently of labelling. The labelling effects we observed were not explained by concurrent chronic disease, having more contact with the health care system/medical providers, or medication use. Further, these associations were consistently of a larger magnitude than factors such as education and income, and were observed across non-Hispanic white, non-Hispanic black, and Mexican-American subpopulations. These data suggest that efforts to increase hypertension screening and awareness may inadvertently but broadly undermine other health benchmarks, that is, health-related quality of life as measured by global SRH. 4, 24 This work contributes to the literature in several ways. First, we replicated a number of similar studies testing labelling effects. [9] [10] [11] [12] [13] [14] 25 Second, we extended this work by showing that labelling effects on SRH are independent of potential confounding by known SRH predictors, such as concurrent chronic disease, 36 SES, 37 and BMI. Since high BMI is associated with hypertension and poorer SRH, it is an especially potent rival hypothesis for labelling effects. 38, 39 Third, the NHANES data provide multiple blood pressure measurements to define hypertensive status, reducing the possibility of misclassification error. 40 In addition, the rigorous training of examiners likely provided more reliable blood pressure measurement than those obtained in typical hospital or clinic settings. 41, 42 Finally, the sample was substantially larger than in previous reports and representative of the adult US population, reinforcing findings from other populationbased studies showing adverse hypertensive labelling effects on quality of life. 13, 15 To the extent that a hypertensive label negatively affects SRH, among truly hypertensive individuals this is offset by the health benefits of subsequent antihypertensive treatment. On the other hand, normotensive persons mislabelled as hypertensive enjoy no such benefit. Based upon this population sample, we estimate that 12.6% of normotensive US adults are labelled as having hypertension. Although most of these people are on antihypertensive medication, some are mislabeled due to factors such as blood pressure variability, poor measurement technique and miscommunication. The potential for adverse labelling effects may be exacerbated by recent guidelines which recommend labelling those with lower blood pressure (i.e., 120-139 mmHg SBP or 80-89 mmHg DBP) as prehypertensive. 1 In any case, the potential negative consequences of mislabelling remain unaddressed in public and private health screening initiatives.
Several limitations of the present work should be considered. The cross-sectional design cannot address the causal direction of this association, and we relied upon self-reports to assess prior hypertension diagnosis (i.e., labelling). However, error in these reports would probably bias the analyses towards the null hypothesis. Looking ahead, longitudinal studies could prospectively document the effects of hypertensive labelling on SRH, and also assess whether such labelling affects clinical outcomes. In this regard, one prospective study found that the adverse effects of labelling on SRH were limited to those taking medication 1 year postlabelling. 27 However, that report was based upon hypertensive participants enrolled in a clinical trial of blood pressure treatment. Other SRH predictors were uncontrolled in the analyses and, in general, participants in clinical trials often report gains in Figure 2 Odds of lower self-rated health for individuals labelled as hypertensive by actual hypertension status and race/ethnicity. All values are adjusted for age, gender, education, annual household income, body mass index, smoking, physician visits in the last 12 months, systolic and diastolic blood pressure and the presence of cancer, stroke, heart attack, and diabetes. CI, confidence interval.
What is known on this topic
Hypertension screening is part of health promotion and disease prevention programmes in industrialized countries. Individuals labelled as having hypertension tend to report low health-related quality of life but this association could be due to other sociodemographic and health risk factors.
What this study adds Hypertension labelling, but not high blood pressure, is associated with poorer self-rated health in a diverse US population sample. This association persisted after adjustment for socioeconomic status, body mass index, and self-reported hypertension medication use and was observed within non-Hispanic white, non-Hispanic black, and Hispanic subpopulations.
Hypertension screening and subsequent labelling may have broad adverse effects on global self-rated health.
SRH probably resulting from the close medical care that they receive. Although we would anticipate different labelling outcomes among the general population, such work may provide the antidote to unwanted labelling effects -more intensive counselling and follow-up. It is possible that if clinicians establish collaborative and empathic relationships with hypertensive individuals the potential negative effects of hypertensive labelling could be diminished. 1 Trials in naturalistic settings using current hypertension guidelines can address this important question.
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